methyl 7-fluoro-1-oxo-2H-isoquinoline-4-carboxylate | 583880-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: methyl 7-fluoro-1-oxo-2H-isoquinoline-4-carboxylate
• CAS: 583880-97-1
• 化学式: C₁₁H₈FNO₃
• 分子量: 221.188
• InChiKey: RMFWKDYOIINUEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 7-fluoro-1-oxo-2H-isoquinoline-4-carboxylate 在 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(2R)-3-[4-(4-chloro-2-methylphenoxy)piperidin-1-yl]-2-hydroxypropyl]-7-fluoro-1-oxo-2H-isoquinoline-4-carboxamide
  参考文献：
  名称：

  Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part II: Optimising in vivo clearance

  摘要：

  The second part of this communication focuses on the resolution of issues surrounding the series of hydroxyamide phenoxypiperidine CCR3/H-1 dual antagonists described in Part I. This involved further structural exploration directed at reducing metabolism and leading to the identification of compound 60 with a greatly improved in vivo pharmacokinetic profile. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.112
• 作为产物：
  描述：

  在 硫酸 、 ammonium acetate 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 生成 methyl 7-fluoro-1-oxo-2H-isoquinoline-4-carboxylate
  参考文献：
  名称：

  Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part II: Optimising in vivo clearance

  摘要：

  The second part of this communication focuses on the resolution of issues surrounding the series of hydroxyamide phenoxypiperidine CCR3/H-1 dual antagonists described in Part I. This involved further structural exploration directed at reducing metabolism and leading to the identification of compound 60 with a greatly improved in vivo pharmacokinetic profile. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.112

文献信息

• Chemical compounds
  申请人：Alcaraz Lilian

  公开号：US20050107428A1

  公开（公告）日：2005-05-19

  The invention provides compounds of formula (I):[Chemical formula should be inserted here. Please see paper copy]wherein: X is CH 2 , O, S(O) 2 or NR 10 ; Y is a bond, CH 2 , NR 35 , CH 2 NH, CH 2 NHC(O), CH(OH), CH(NHCOR 33 ), CH(NHSO 2 R 34 ), CH 2 O or CH 2 S; Z is C(O), or when Y is a bond Z can also be S(O) 2 ; R 1 is optionally substituted aryl, optionally substituted heterocyclyl or C 4-6 cycloalkyl fused to a benzene ring; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 , R 9 , R 10 , R 32 , R 33 , R 34 and R 35 are as defined herein; are modulators of chemokine (especially CCR3) activity (for use in, for example, treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.

  该发明提供了式（I）的化合物：[化学式应在此处插入。请参见纸质副本]其中：X为CH2，O，S（O）2或NR10；Y为键，CH2，NR35，CH2NH，CH2NHC（O），CH（OH），CH（NHCOR33），CH（NHSO2R34），CH2O或CH2S；Z为C（O），或当Y为键时，Z也可以是S（O）2；R1是可选择的取代芳基，可选择的取代杂环基或与苯环融合的C4-6环烷基；R2、R3、R4、R5、R6、R7和R8、R9、R10、R32、R33、R34和R35如本文所定义；是趋化因子（特别是CCR3）活性调节剂（例如用于治疗哮喘）。该发明还提供了制备4-（3,4-二氯苯氧基）哌啶的方法，该方法有用于制备该发明的某些化合物的中间体。
• CHEMICAL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1478624B1

  公开（公告）日：2010-09-08
• US7709500B2
  申请人：——

  公开号：US7709500B2

  公开（公告）日：2010-05-04
• Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part II: Optimising in vivo clearance
  作者：Mark Furber、Lilian Alcaraz、Christopher Luckhurst、Ash Bahl、Haydn Beaton、Keith Bowers、John Collington、Rebecca Denton、David Donald、Elizabeth Kinchin、Cathy MacDonald、Aaron Rigby、Rob Riley、Matt Soars、Brian Springthorpe、Peter Webborn

  DOI：10.1016/j.bmcl.2012.09.112

  日期：2012.12

  The second part of this communication focuses on the resolution of issues surrounding the series of hydroxyamide phenoxypiperidine CCR3/H-1 dual antagonists described in Part I. This involved further structural exploration directed at reducing metabolism and leading to the identification of compound 60 with a greatly improved in vivo pharmacokinetic profile. (C) 2012 Elsevier Ltd. All rights reserved.